Can a Cholesterol-Lowering injection help lung cancer patients stay on a key treatment?
NCT ID NCT07674368
First seen Jun 29, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether recakimab, an injectable drug that lowers cholesterol, can safely reduce high cholesterol caused by the lung cancer medication lorlatinib. The trial enrolls about 29 adults with advanced ALK-positive non-small cell lung cancer who developed high cholesterol while taking lorlatinib. Participants receive recakimab injections every 8 weeks for up to 32 weeks, and researchers track changes in cholesterol levels and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recakimab (a PCSK9 inhibitor injection)
What this could lead to
If it works, this could offer a way to manage a common side effect of a key lung cancer treatment, potentially allowing more people to stay on lorlatinib longer.
What could go wrong
This is a small, early-phase study with only 29 participants and no comparison group, so results may not apply broadly. The cholesterol-lowering effect may be modest or not sustained.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••